Icon

Avadel Pharmaceuticals PLC Stock Analysis and Price Target COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 11.41

-0.07 (-0.61)%

USD 1.05B

0.23M

USD 20.00(+75.28%)

USD 2.00 (-82.47%)

Icon

AVDL

Avadel Pharmaceuticals PLC (USD)
COMMON STOCK | NSD
USD 11.41
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.05B

USD 2.00 (-82.47%)

USD 11.41

Avadel Pharmaceuticals PLC Stock Forecast

USD 20.00
(+75.28%)

Based on the Avadel Pharmaceuticals PLC stock forecast from 5 analysts, the average analyst target price for Avadel Pharmaceuticals PLC is USD 20.00 over the next 12 months. Avadel Pharmaceuticals PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avadel Pharmaceuticals PLC is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Avadel Pharmaceuticals PLC’s stock price was USD 11.41. Avadel Pharmaceuticals PLC’s stock price has changed by -0.17% over the past week, +16.07% over the past month and +45.54% over the last year.

No recent analyst target price found for Avadel Pharmaceuticals PLC
No recent average analyst rating found for Avadel Pharmaceuticals PLC

Company Overview Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narco...Read More

https://www.avadel.com

10 Earlsfort Terrace, Dublin, Ireland, 2

41

December

USD

USA

Adjusted Closing Price for Avadel Pharmaceuticals PLC (AVDL)

Loading...

Unadjusted Closing Price for Avadel Pharmaceuticals PLC (AVDL)

Loading...

Share Trading Volume for Avadel Pharmaceuticals PLC Shares

Loading...

Compare Performance of Avadel Pharmaceuticals PLC Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AVDL

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Avadel Pharmaceuticals PLC (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VTRS
Viatris Inc -0.01 (-0.11%) USD11.31B 6.25 6.97

ETFs Containing AVDL

Symbol Name AVDL's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Avadel Pharmaceuticals PLC (AVDL) Stock

Based on ratings from 5 analysts Avadel Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.

AVDL stock's dividend yield is 0.40%. Our analysis grades AVDL stock's dividend yield at F. This means that AVDL stock's dividend yield is above 4% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this AVDL may be a poor dividend stock for its sector.

Based on targets from 5 analysts, the average taret price for AVDL is USD 20.00 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 18.

AVDL stock's Price/Earning ratio is 60.92. Our analysis grades AVDL stock's Price / Earning ratio at F. This means that AVDL stock's Price/Earning ratio is above 83% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this AVDL may be a overvalued for its sector.

The last closing price of AVDL's stock was USD 11.41.

The most recent market capitalization for AVDL is USD 1.05B.

Based on targets from 5 analysts, the average taret price for AVDL is projected at USD 20.00 over the next 12 months. This means that AVDL's stock price may go up by +75.28% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...